Arcturus Therapeutics (NASDAQ:ARCT) Rating Reiterated by William Blair

Arcturus Therapeutics (NASDAQ:ARCT)‘s stock had its “outperform” rating reissued by investment analysts at William Blair in a report released on Monday, RTT News reports.

Other analysts have also issued reports about the company. StockNews.com assumed coverage on Arcturus Therapeutics in a report on Thursday, October 5th. They set a “hold” rating for the company. HC Wainwright reiterated a “buy” rating and set a $51.00 price target on shares of Arcturus Therapeutics in a research note on Wednesday, September 27th. Cantor Fitzgerald reissued an “overweight” rating and issued a $54.00 price objective on shares of Arcturus Therapeutics in a research note on Tuesday, August 22nd. Wells Fargo & Company boosted their target price on Arcturus Therapeutics from $35.00 to $45.00 in a report on Monday, July 17th. Finally, Guggenheim restated a “buy” rating on shares of Arcturus Therapeutics in a report on Friday, July 14th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat, Arcturus Therapeutics presently has a consensus rating of “Hold” and an average target price of $41.29.

Arcturus Therapeutics Stock Up 6.4 %

Shares of Arcturus Therapeutics stock opened at $19.59 on Monday. The stock has a market cap of $521.09 million, a PE ratio of 6.78 and a beta of 2.59. The business has a fifty day simple moving average of $24.97 and a 200-day simple moving average of $27.79. Arcturus Therapeutics has a 12 month low of $14.21 and a 12 month high of $37.75.

Arcturus Therapeutics (NASDAQ:ARCT) last issued its earnings results on Monday, August 7th. The biotechnology company reported ($1.98) EPS for the quarter, missing the consensus estimate of $0.09 by ($2.07). Arcturus Therapeutics had a return on equity of 20.75% and a net margin of 30.36%. The business had revenue of $10.52 million during the quarter, compared to analyst estimates of $71.05 million. Analysts expect that Arcturus Therapeutics will post -3.56 EPS for the current fiscal year.

Insider Activity at Arcturus Therapeutics

In related news, COO Pad Chivukula sold 5,000 shares of the company’s stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $18.72, for a total value of $93,600.00. Following the completion of the transaction, the chief operating officer now directly owns 499,448 shares in the company, valued at $9,349,666.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last ninety days, insiders sold 15,000 shares of company stock worth $378,900. 13.80% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. MetLife Investment Management LLC grew its position in Arcturus Therapeutics by 66.3% in the first quarter. MetLife Investment Management LLC now owns 12,327 shares of the biotechnology company’s stock valued at $332,000 after acquiring an additional 4,915 shares during the period. Dimensional Fund Advisors LP grew its position in Arcturus Therapeutics by 190.3% in the first quarter. Dimensional Fund Advisors LP now owns 217,572 shares of the biotechnology company’s stock valued at $5,866,000 after acquiring an additional 142,633 shares during the period. Vanguard Group Inc. grew its position in Arcturus Therapeutics by 0.5% in the first quarter. Vanguard Group Inc. now owns 1,153,513 shares of the biotechnology company’s stock valued at $31,099,000 after acquiring an additional 6,291 shares during the period. Federated Hermes Inc. grew its position in Arcturus Therapeutics by 1.8% in the first quarter. Federated Hermes Inc. now owns 3,761,900 shares of the biotechnology company’s stock valued at $101,421,000 after acquiring an additional 66,971 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its position in Arcturus Therapeutics by 2.5% in the first quarter. Charles Schwab Investment Management Inc. now owns 154,551 shares of the biotechnology company’s stock valued at $4,167,000 after acquiring an additional 3,704 shares during the period. 88.87% of the stock is currently owned by institutional investors and hedge funds.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.